ClinicalTrials.gg
TerminatedNCT02258607Updated Feb 1, 2019

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

A Phase 1 interventional study of Momelotinib (MMB) and Trametinib in Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer, sponsored by Sierra Oncology LLC - a GSK company. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2016, 10 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
37th of 47
21 · median 88
Started
2015
with 1 other
Phase 1
17 of 54
none open now
Registered
32nd of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 37th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2015, is one of 17 in phase 1, and was the 32nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is conducted in two phases. The Dose-finding Lead-in Phase, Part A, will evaluate the safety and determine the maximum tolerated dose (MTD) of momelotinib (MMB) when combined with trametinib. Once the MTD of momelotinib (MMB) is determined, the study will proceed to the Dose-finding Lead-in Phase, Part B, to determine the MTD of trametinib. After the MTD is established, the study may proceed to an expansion phase to determine the efficacy, safety, and tolerability of MMB combined with trametinib at the MTD in participants with kirsten rat sarcoma viral oncogene homolog (KRAS) mutated metastatic non-small cell lung cancer (NSCLC). Each treatment cycle will consist of 28 days and treatment will continue in the absence of disease progression, unacceptable toxicity, consent withdrawal, or participant's refusal of treatment.

03

Conditions studied

  • Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals with KRAS-mutated or recurrent non-small cell lung cancer
  • Radiologic documentation of disease progression
  • per v1.1
  • Adequate organ function defined as follows:

    • Hepatic: Total conjugated ≤ 1.25 x (ULN); (AST) and alanine transaminase (ALT) \< 3 x upper limit of normal (ULN) or \< 5 x ULN in the setting of liver metastases
  • Hematological: (ANC) ≥ 1.5 x 10\^9/L, ≥ 100 x 10\^9/L, ≥ 9 g/dL

    • Renal: Serum creatinine \< 1.5 x ULN OR calculated (CLcr) ≥ 60 ml/min
  • Adequate (LVEF) ≥ 50%
  • (ECOG) Performance Status of 0 or 1
  • Negative serum pregnancy test for females

Key Exclusion Criteria:

  • Less than or equal to 3 weeks since receiving treatment with biologic, small molecule, chemotherapy or other agent for non-small cell lung cancer and 28 days since any prior immunotherapy (such as nivolumab)
  • History of a concurrent or second , except for specified exceptions in the protocol or any other cancer that has been in complete remission for ≥ 5 years
  • Known positive status for (HIV)
  • Chronic active or acute viral hepatitis A, B, or C infection or or C carrier
  • Presence of ≥ Grade 2 peripheral neuropathy
  • , or spinal cord compression. Individuals with brain metastases are allowed if they have been treated with irradiation or surgery, are clinically stable without treatment. Individuals with documented are not eligible
  • A history of uveitis and/or scleritis
  • Retinal pathology beyond normal age-related processes
  • Evidence of a retinal vein occlusion on ophthalmological exam or a history of retinal vein occlusion
  • History of newly diagnosed or uncontrolled glaucoma/intraocular pressure > 21 mm Hg as measured by tonography
  • Use of daily and/or chronic oral or ocular steroids. Individuals must be off daily steroids for at least 3 weeks prior to enrolling into the trial
  • History of interstitial pneumonitis
  • History of long syndrome or whose corrected QT interval (QTc) measured (Fridericia method) at screening is prolonged (> 480 ms for males and females)

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Momelotinib (MMB) dose escalation

    Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.

    Drug: Momelotinib (MMB) · Drug: Trametinib

  • Experimental
    Trametinib dose escalation

    Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.

    Drug: Momelotinib (MMB) · Drug: Trametinib

  • Experimental
    Momelotinib (MMB)+trametinib

    Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.

    Drug: Momelotinib (MMB) · Drug: Trametinib

Interventions

  • Momelotinib (MMB) tablet(s) administered orally once or twice daily

    Also known as: GS-0387, CYT387

  • Trametinib tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. For the Dose-finding Lead-in Phase, incidence of dose limiting toxicities (DLTs)

    Dose limiting toxicities (DLTs) refer to toxicities experienced during the first 28 days of treatment that have been judged to be clinically significant and at least possibly related to study treatment.

    Time frame: Up to 28 days

  2. For Expansion Phase, disease control rate (DCR) at Week 8

    Disease control rate (DCR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) or stable disease (SD) as assessed by Response Evaluation Criteria In Solid Tumor (RECIST) v1.1.

    Time frame: Week 8

Secondary outcomes

  1. For the Dose-finding Lead-in Phase, disease control rate (DCR) at Week 8

    Time frame: Week 8

  2. For the Dose-finding Lead-in Phase, overall survival

    Overall survival is defined as the interval from first dose of study drug to death from any cause.

    Time frame: Up to 2 years

  3. For the Dose-finding Lead-in Phase, progression free survival (PFS)

    Progression free survival (PFS) is defined as the interval from first dose date of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.

    Time frame: Up to 2 years

  4. For the Dose-finding Lead-in Phase, overall response rate (ORR)

    Overall response rate (ORR) is defined as the proportion of participants who achieve a CR or PR as assessed by RECIST v1.1.

    Time frame: Up to 2 years

  5. For the Dose-finding Lead-in Phase, plasma pharmacokinetics (PK) parameters of momelotinib (MMB) and major metabolite GS-644603 as measured by Cmax and AUCtau

    This composite endpoint will measure the plasma PK profile of momelotinib (MMB) and GS-644603. The following parameters will be measured: * Cmax: maximum observed concentration of drug in plasma * AUCtau: concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)

    Time frame: Days 1 and 15 (Cycle 1 only)

  6. For Expansion Phase, overall survival

    Time frame: Up to 2 years

  7. For Expansion Phase, progression free survival (PFS)

    Time frame: Up to 2 years

  8. For Expansion Phase, overall response rate (ORR)

    Time frame: Up to 2 years

07

Study locations

5 sites
  • Duarte, California, United States
  • Sacramento, California, United States
  • Boston, Massachusetts, United States
  • Fairfax, Virginia, United States
  • Spokane, Washington, United States
08

References and documents

Publications

  • Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, Kong S, Koczywas M. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. Clin Lung Cancer. 2018 Nov;19(6):e853-e859. doi: 10.1016/j.cllc.2018.07.004. Epub 2018 Aug 4. PubMed 30087028 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Jul 2016, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2014
First posted
Oct 7, 2014
StartActual
Mar 11, 2015
Primary completionActual
Jul 19, 2016
CompletionActual
Feb 27, 2017
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02258607
Responsible party
Sponsor
First posted
Oct 7, 2014
Start date
Mar 11, 2015
Primary completion
Jul 19, 2016
Completion
Feb 27, 2017
Last update
Feb 1, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion